Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Files Patent Infringement Suit Against GE Healthcare

NEW YORK (GenomeWeb News) – Invitrogen last week filed a patent infringement suit against GE Healthcare and other unnamed defendants for allegedly infringing six patents, four of which expired earlier this year.
Invitrogen said in its complaint filed in the US District Court for the Eastern District of Texas Tyler Division that GE Healthcare’s CyScript reverse transcriptase enzymes and kits infringe all six of the patents.
The US patents at issue are Nos. 6,610,522; 6,589,768; 6,063,608; 5,668,005; 5,244,797; 5,405,776. All but the last two expired in January.
Invitrogen is seeking an injunction against GE for sales of products that it believes currently are infringing the last two patents. It also is seeking royalties on past sales of products that it believes GE has infringed. Invitrogen alleged in the complaint that GE’s infringement was willful, which means that it would be entitled to triple damages.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.